# Acceleron Pharma Inc. (XLRN)

Source: https://www.quantisnow.com/company/XLRN
Generated: 2026-11-16T08:05:17.053Z

- Ticker: XLRN
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2013
- Website: acceleronpharma.com

## About

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients. It has a license agreements with the Salk Institute for Biological Studies for the cloning of type II activin receptors; and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

## Latest XLRN news and filings

- 2022-06-02 12:00 UTC [Qiming Venture Partners USA Announces $260 Million US Healthcare Fund III and Addition of New Partner, Isaac Ciechanover](https://www.quantisnow.com/insight/qiming-venture-partners-usa-announces-260-million-us-healthcare-fund-2978073)
- 2021-12-02 14:00 UTC [SEC Form 15-12B] [SEC Form 15-12B filed by Acceleron Pharma Inc.](https://www.quantisnow.com/insight/sec-form-15-12b-filed-by-acceleron-pharma-inc-2087403)
- 2021-11-24 20:48 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Acceleron Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-acceleron-pharma-inc-amendment-2055699)
- 2021-11-22 14:12 UTC [SEC Form 4] [SEC Form 4: Zakrzewski Joseph S closing all direct ownership in the company to cover withholding tax](https://www.quantisnow.com/insight/sec-form-4-zakrzewski-joseph-s-closing-all-direct-ownership-2040381)
- 2021-11-22 14:11 UTC [SEC Form 4] [SEC Form 4: Malik Kemal closing all direct ownership in the company (withholding obligation)](https://www.quantisnow.com/insight/sec-form-4-malik-kemal-closing-all-direct-ownership-in-2040372)
- 2021-11-22 14:10 UTC [SEC Form 4] [SEC Form 4: Hite Christopher closing all direct ownership in the company to satisfy withholding tax](https://www.quantisnow.com/insight/sec-form-4-hite-christopher-closing-all-direct-ownership-in-2040366)
- 2021-11-22 14:09 UTC [SEC Form 4] [SEC Form 4: Smith Karen L. closing all direct ownership in the company to satisfy withholding tax](https://www.quantisnow.com/insight/sec-form-4-smith-karen-l-closing-all-direct-ownership-2040355)
- 2021-11-22 14:08 UTC [SEC Form 4] [SEC Form 4: Mccourt Thomas A closing all direct ownership in the company (tax liability)](https://www.quantisnow.com/insight/sec-form-4-mccourt-thomas-a-closing-all-direct-ownership-2040343)
- 2021-11-22 14:08 UTC [SEC Form 4] [SEC Form 4: Kearney Terrence C closing all direct ownership in the company (for tax liability)](https://www.quantisnow.com/insight/sec-form-4-kearney-terrence-c-closing-all-direct-ownership-2040340)
- 2021-11-22 14:07 UTC [SEC Form 4] [SEC Form 4: Hamill Laura closing all direct ownership in the company (tax liability)](https://www.quantisnow.com/insight/sec-form-4-hamill-laura-closing-all-direct-ownership-in-2040337)
- 2021-11-22 14:06 UTC [SEC Form 4] [SEC Form 4: Nader Francois closing all direct ownership in the company to cover withholding tax](https://www.quantisnow.com/insight/sec-form-4-nader-francois-closing-all-direct-ownership-in-2040328)
- 2021-11-22 14:05 UTC [SEC Form 4] [SEC Form 4: Veness Adam M closing all direct ownership in the company (for tax liability)](https://www.quantisnow.com/insight/sec-form-4-veness-adam-m-closing-all-direct-ownership-2040321)
- 2021-11-22 14:04 UTC [SEC Form 4] [SEC Form 4: Kango Sujay closing all direct ownership in the company (for tax liability)](https://www.quantisnow.com/insight/sec-form-4-kango-sujay-closing-all-direct-ownership-in-2040316)
- 2021-11-22 14:04 UTC [SEC Form 4] [SEC Form 4: Backstrom Jay T. closing all direct ownership in the company (withholding obligation)](https://www.quantisnow.com/insight/sec-form-4-backstrom-jay-t-closing-all-direct-ownership-2040302)
- 2021-11-22 14:03 UTC [SEC Form 4] [SEC Form 4: Mclaughlin Kevin F closing all direct ownership in the company to cover taxes](https://www.quantisnow.com/insight/sec-form-4-mclaughlin-kevin-f-closing-all-direct-ownership-2040298)
- 2021-11-22 14:02 UTC [SEC Form 4] [SEC Form 4: Dable Habib J closing all direct ownership in the company to cover withholding tax](https://www.quantisnow.com/insight/sec-form-4-dable-habib-j-closing-all-direct-ownership-2040294)
- 2021-11-22 13:52 UTC [SEC Form 8-K] [Acceleron Pharma Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/acceleron-pharma-inc-filed-sec-form-8-k-completion-of-acquisition-2040042)
- 2021-11-22 13:41 UTC [SEC Form 25-NSE filed by Acceleron Pharma Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-acceleron-pharma-inc-2039961)
- 2021-11-22 12:02 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by Acceleron Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-acceleron-pharma-inc-amendment-2039018)
- 2021-11-22 12:01 UTC [SEC Schedule TOT] [SEC Form SC TO-T/A filed by Acceleron Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-by-acceleron-pharma-inc-amendment-2039013)
- 2021-11-22 11:45 UTC [Merck Completes Acquisition of Acceleron Pharma Inc.](https://www.quantisnow.com/insight/merck-completes-acquisition-of-acceleron-pharma-inc-2038820)
- 2021-11-19 23:06 UTC [Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.](https://www.quantisnow.com/insight/merck-completes-tender-offer-to-acquire-acceleron-pharma-inc-2037275)
- 2021-11-17 21:26 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by Acceleron Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-acceleron-pharma-inc-amendment-2024787)
- 2021-11-17 19:26 UTC [Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's Inadequate Offer](https://www.quantisnow.com/insight/avoro-capital-urges-acceleron-shareholders-not-to-tender-into-mercks-2023896)
- 2021-11-17 12:25 UTC [SEC Schedule TOT] [SEC Form SC TO-T/A filed by Acceleron Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-by-acceleron-pharma-inc-amendment-2020729)
- 2021-11-17 12:00 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by Acceleron Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-acceleron-pharma-inc-amendment-2020575)
- 2021-11-17 11:45 UTC [Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.](https://www.quantisnow.com/insight/merck-announces-expiration-of-hart-scott-rodino-act-waiting-period-and-extension-2020405)
- 2021-11-12 21:15 UTC [SEC Form 4] [SEC Form 4: Veness Adam M exercised 4,500 shares at a strike of $29.37, increasing direct ownership by 24% to 23,423 units](https://www.quantisnow.com/insight/sec-form-4-veness-adam-m-exercised-4500-shares-at-2002733)
- 2021-11-12 12:00 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by Acceleron Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-acceleron-pharma-inc-amendment-1999208)
- 2021-11-10 17:24 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Acceleron Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-acceleron-pharma-inc-amendment-1990251)
- 2021-11-10 16:36 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by Acceleron Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-acceleron-pharma-inc-amendment-1989920)
- 2021-11-09 22:31 UTC [Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck's Inadequate Offer](https://www.quantisnow.com/insight/avoro-capital-releases-presentation-detailing-why-acceleron-shareholders-should-not-1985324)
- 2021-11-08 22:16 UTC [SEC Schedule TOT] [SEC Form SC TO-T/A filed by Acceleron Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-by-acceleron-pharma-inc-amendment-1977398)
- 2021-11-08 22:15 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by Acceleron Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-acceleron-pharma-inc-amendment-1977378)
- 2021-11-08 21:30 UTC [Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.](https://www.quantisnow.com/insight/merck-announces-receipt-of-antitrust-clearance-in-germany-and-austria-1976770)
- 2021-11-04 20:10 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Acceleron Pharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-acceleron-pharma-inc-1963612)
- 2021-11-04 20:05 UTC [SEC Form 8-K] [Acceleron Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/acceleron-pharma-inc-filed-sec-form-8-k-results-of-operations-1963415)
- 2021-10-30 01:48 UTC [SEC Schedule TOT] [SEC Form SC TO-T/A filed by Acceleron Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-by-acceleron-pharma-inc-amendment-1936486)
- 2021-10-30 01:45 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by Acceleron Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-acceleron-pharma-inc-amendment-1936461)
- 2021-10-29 20:34 UTC [Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc.](https://www.quantisnow.com/insight/merck-announces-withdrawal-and-refiling-under-the-hart-scott-rodino-act-and-1935005)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/XLRN
- Earnings history: https://www.quantisnow.com/earnings/XLRN
- Dividend history: https://www.quantisnow.com/dividends/XLRN
- Insider transactions: https://www.quantisnow.com/insiders/XLRN
- Options chain: https://www.quantisnow.com/options/XLRN
- SEC 8-K filings only: https://www.quantisnow.com/company/XLRN/8-k
- RSS and alerts for XLRN: https://www.quantisnow.com/docs/rss-feeds.md
